IVEVF — Inventiva S.A.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1756594 ·
Last close
$3.59
Market Cap
$848.03M
52W High
$5.33
52W Low
$3.59
ADV30
3
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 249,511,000 | 99,312,000 | 278,033,000 |
| Jun 2025 | — | — | — | — | 178,955,000 | 122,076,000 | 187,863,000 |
| Dec 2024 | — | — | — | — | 118,967,000 | 96,563,000 | 225,613,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-354,138,000
Inventory
$0
Receivables
$9,121,000
ST Investments
$131,558,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$6,761,000
EBITDA
$-132,497,000
Free Cash Flow
$-200,711,632
Enterprise Value
$876,720,832
Total Cash
$99,839,000
Total Debt
$230,890,000
Shares Out
236,220,651
Trailing EPS
$-2.16
Book Value
$-0.17
ROE
—
ROA
-45.1%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,483,000 | -132,883,000 | -354,138,000 | 249,511,000 | 278,033,000 | — | -104,884,000 |
| Dec 2024 | 9,198,000 | -93,989,000 | -184,212,000 | 118,967,000 | 225,613,000 | — | -85,928,000 |
| Dec 2023 | 17,477,000 | -102,665,000 | -110,426,000 | 69,561,000 | 101,592,000 | — | -81,614,000 |
| Dec 2022 | 12,179,000 | -56,857,000 | -54,274,000 | 116,004,000 | 70,528,000 | — | -44,928,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.06
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OMER | OMEROS CORP | $856.92M | $11.84 | — |
| ABUS | Arbutus Biopharma Corp | $857.31M | $4.34 | — |
| ANNX | Annexon, Inc. | $834.78M | $5.09 | — |
| GERN | GERON CORP | $827.56M | $1.29 | — |
| TBPH | Theravance Biopharma, Inc. | $873.82M | $16.86 | — |
News headlines (Yahoo Finance, 1h cache)
Correction: Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
2026-07-30 20:00 · Yahoo
Inventiva Announces Preliminary Financial Results for the First Half of 2026¹
2026-07-29 20:00 · Yahoo
Inventiva (IVA) Announces Issuance of New EIB Warrants, Completes EIB Warrant Restructuring
2026-07-15 08:53 · Yahoo
Inventiva (ENXTPA:IVA) Puts Its MASH Narrative To The Test After A Recent Rebound
2026-07-12 13:08 · Yahoo
Inventiva Announces Completion of the EIB Warrant Restructuring with the Issuance of New EIB Warrants
2026-07-09 20:20 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise Thursday
2026-07-09 15:10 · Yahoo
Results of the Votes of the Combined Shareholders’ General Meeting of June 30, 2026
2026-07-02 20:00 · Yahoo
Inventiva S.A. (IVA) is One of the Best Stocks Under $10 Offering More Than 50% Upside
2026-06-30 16:34 · Yahoo
After Plunging 30.8% in 4 Weeks, Here's Why the Trend Might Reverse for Inventiva (IVA)
2026-06-29 13:35 · Yahoo
Claret Capital Partners participates in €130m financing for Inventiva
2026-06-16 09:12 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.